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Down syndrome is the most common chromosomal
abnormality in pregnancy. Non-invasive prenatal diagnosis
(NIPD) of DS screening in the first trimester of pregnancy
involves the nuchal transclucency hyperechographic scan-
ning combined to the analysis of b-subunit of human
chorionic gonadotropin (b-hCG) and pregnancy associated
plasma protein-A (PAPP-A). Application of proteomics for
the identification of potential biomarkers for the prenatal
screening of DS revealed a group of proteins (AMBP, SAP,
CERU, CLUS, APOE, AFAM, TTHY) differentially
expressed during the 15th week of pregnancy in the mater-
nal plasma of women carrying DS fetuses compared to
normal pregnancies [1,2]. These proteins could act as
potential markers for the prevention of DS by NIPD. From
this protein group we selected SAP because the specific
protein seems to be the most promising for the NIPD of
DS, since several studies have indicated SAP involvement
to Alzheimer’s disease, a phenotype close to DS. In the
present study, through western blot analysis we evaluated
the capability of SAP to act as a reliable biomarker for the
NIPD of DS fetuses at the 10th -12th and 15th -16th week
of pregnancy [3- 5]. We analyzed 25 serum samples from
women carrying DS fetuses and 75 samples of women
with normal fetuses at the 10th-12th week of pregnancy.
Furthermore SAP levels were evaluated in 12 plasma sam-
ples from women with DS fetuses and 15 samples of nor-
mal pregnancies at the 15th-16th week of pregnancy. At
the10th - 12th week of pregnancy we found that SAP levels
were elevated in 24 out of the 25 DS pregnancies com-
pared to normal controls. At the 15th -16th week of preg-
nancy SAP was increased in all the DS pregnancies
compared to normal controls. Quantitative densitometric
analysis indicated that at the 10th-12th week of pregnancy
SAP was increased by a mean of 20% in DS pregnancies
compared to controls while at the 15th - 16th week of preg-
nancy SAP was increased by a mean of 40%. These results
indicate that SAP could be a reliable marker for the preven-
tion of DS fetuses in maternal plasma early at pregnancy.
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